Northland named Heron Therapeutics as a “2024 Top Pick” as the firm anticipates momentum in shares to continue considering fundamental improvements and near-term catalysts that include the anticipated label expansion of Zynrelef, the launch of the vial access needle anticipated in Q3, and the ramp-up of Aponvie. The firm keeps an Outperform rating and $9 price target on Heron shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HRTX:
- Biotech Alert: Searches spiking for these stocks today
- Heron Therapeutics price target lowered to $2.50 from $5.50
- Heron Therapeutics price target lowered to $4 from $5 at Needham
- Heron Therapeutics sees FY24 revenue $138M-$158M, consensus $156.57M
- Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance